{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:04:43Z","timestamp":1792033483321,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","bmn.com","clinicalkey.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.tips.2024.06.003","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T12:12:58Z","timestamp":1721650378000},"page":"671-677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Multiple hERG channel blocking pathways: implications for macromolecules"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5396-4928","authenticated-orcid":false,"given":"Bernd J.","family":"Z\u00fcnkler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2024.06.003_bb0005","series-title":"Topic S7B. The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. CHMP\/ICH\/423\/02","author":"International Council on Harmonisation","year":"2005"},{"key":"10.1016\/j.tips.2024.06.003_bb0010","series-title":"Clinical and nonclinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential \u2013 questions and answers. EMA\/CHMP\/ICH\/415588\/2020","author":"International Council on Harmonisation E14\/S7B Implementation Working Group","year":"2022"},{"key":"10.1016\/j.tips.2024.06.003_bb0015","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.tips.2017.06.004","article-title":"Towards a structural view of drug binding to hERG K+ channels","volume":"38","author":"Vandenberg","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tips.2024.06.003_bb0020","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ahj.2013.11.004","article-title":"Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium","volume":"167","author":"Sager","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.tips.2024.06.003_bb0025","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3389\/fphar.2019.01572","article-title":"An update on the structure of hERG","volume":"10","author":"Butler","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2024.06.003_bb0030","doi-asserted-by":"crossref","first-page":"12329","DOI":"10.1073\/pnas.210244497","article-title":"A structural basis for drug-induced long QT syndrome","volume":"97","author":"Mitcheson","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2024.06.003_bb0035","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cell.2017.03.048","article-title":"Cryo-EM structure of the open human ether-\u00e0-go-go-related K+ channel hERG","volume":"169","author":"Wang","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.tips.2024.06.003_bb0040","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.str.2020.12.007","article-title":"Cryo-EM structure of K+-bound hERG channel complexed with the blocker astemizole","volume":"29","author":"Asai","year":"2021","journal-title":"Structure"},{"key":"10.1016\/j.tips.2024.06.003_bb0045","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/cpt.3047","article-title":"ICH S7B in vitro assays do not address mechanisms of QTC prolongation for peptides and proteins \u2013 data in support of not needing dedicated QTC studies","volume":"114","author":"Wu","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.tips.2024.06.003_bb0050","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.vascn.2008.04.001","article-title":"Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics","volume":"58","author":"Vargas","year":"2008","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.tips.2024.06.003_bb0055","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/1087057114560698","article-title":"Discovery of functional antibodies targeting ion channels","volume":"20","author":"Wilkinson","year":"2015","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.tips.2024.06.003_bb0060","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.toxicon.2012.03.024","article-title":"Toxin modulators and blockers of hERG K+ channels","volume":"60","author":"Jim\u00e9nez-Vargas","year":"2012","journal-title":"Toxicon"},{"key":"10.1016\/j.tips.2024.06.003_bb0065","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/CIRCULATIONAHA.115.009800","article-title":"Pathogenesis of the novel autoimmune-associated long-QT syndrome","volume":"132","author":"Yue","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.tips.2024.06.003_bb0070","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/sj.bjp.0705335","article-title":"Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652","volume":"139","author":"Milnes","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2024.06.003_bb0075","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/sj.bjp.0705336","article-title":"Drug binding to HERG channels: evidence for a \u2018non-aromatic\u2019 binding site for fluvoxamine","volume":"139","author":"Mitcheson","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2024.06.003_bb0080","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.bbrc.2006.01.008","article-title":"Erythromycin block of the HERG K+ channel: accessibility to F656 and Y652","volume":"341","author":"Duncan","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tips.2024.06.003_bb0085","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.14385","article-title":"The macrolide drug erythromycin does not protect the hERG channel from inhibition by thioridazine and terfenadine","volume":"8","author":"El Harchi","year":"2020","journal-title":"Physiol. Rep."},{"key":"10.1016\/j.tips.2024.06.003_bb0090","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1113\/JP273142","article-title":"A multiscale computational modelling approach predicts mechanisms of female sex risk in the setting of arousal-induced arrhythmias","volume":"595","author":"Yang","year":"2017","journal-title":"J. Physiol."},{"key":"10.1016\/j.tips.2024.06.003_bb0095","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1111\/bph.13859","article-title":"Modulation of Kv11.1 (hERG) channels by 5-(((1H-indazol-5-yl)oxy)methyl)-N-(4-(trifluoromethoxy)phenyl)pyrimidin-2-amine (ITP-2), a novel small molecule activator","volume":"174","author":"Sale","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2024.06.003_bb0100","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/toxsci\/kfq011","article-title":"Interactions at human ether-\u00e0-go-go-related gene channels","volume":"114","author":"Friemel","year":"2010","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tips.2024.06.003_bb0105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.vascn.2013.10.005","article-title":"Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies","volume":"69","author":"Kim","year":"2014","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.tips.2024.06.003_bb0110","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1073\/pnas.1220143110","article-title":"Differential hERG ion channel activity of ultrasmall gold nanoparticles","volume":"110","author":"Leifert","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2024.06.003_bb0115","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.toxrep.2021.03.022","article-title":"Safety pharmacology of self-assembled-micelle inhibitory RNA-targeting amphiregulin (SAMiRNA-AREG), a novel siRNA nanoparticle platform","volume":"8","author":"Kim","year":"2021","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.tips.2024.06.003_bb0120","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1161\/CIRCULATIONAHA.120.050098","article-title":"MicroRNA biophysically modulates cardiac action potential by direct binding to ion channel","volume":"143","author":"Yang","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.tips.2024.06.003_bb0125","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1085\/jgp.69.4.497","article-title":"Local anesthetics: hydrophilic and hydrophobic pathways for the drug\u2013receptor reaction","volume":"69","author":"Hille","year":"1977","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.tips.2024.06.003_bb0130","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3389\/fphar.2020.00735","article-title":"Hydrophobic drug\/toxin binding sites in voltage-dependent K+ and Na+ channels","volume":"11","author":"Van Theemsche","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2024.06.003_bb0135","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/mol.118.115642","article-title":"The pore\u2013lipid interface: role of amino-acid determinants of lipophilic access by ivabradine to the hERG1 pore domain","volume":"96","author":"Perissinotti","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tips.2024.06.003_bb0140","doi-asserted-by":"crossref","first-page":"7899","DOI":"10.1007\/s00018-021-03967-8","article-title":"Inhibition of the hERG potassium channel by phenanthrene: a polycyclic aromatic hydrocarbon pollutant","volume":"78","author":"Al-Moubarak","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.tips.2024.06.003_bb0145","doi-asserted-by":"crossref","DOI":"10.1038\/srep24182","article-title":"New potential binding determinant for hERG channel inhibitors","volume":"6","author":"Saxena","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2024.06.003_bb0150","doi-asserted-by":"crossref","first-page":"C1251","DOI":"10.1152\/ajpcell.00036.2005","article-title":"\u03a9-3 and \u03a9-6 polyunsaturated fatty acids block HERG channels","volume":"289","author":"Guizy","year":"2005","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.tips.2024.06.003_bb0155","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neulet.2018.05.019","article-title":"Lipid roles in hERG function and interactions with drugs","volume":"700","author":"Kudaibergenova","year":"2019","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.tips.2024.06.003_bb0160","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fphys.2017.00043","article-title":"Actions and mechanisms of polyunsaturated fatty acids on voltage-gated ion channels","volume":"8","author":"Elinder","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/j.tips.2024.06.003_bb0165","doi-asserted-by":"crossref","first-page":"C74","DOI":"10.1152\/ajpcell.00462.2009","article-title":"Ceramide modulates HERG potassium channel gating by translocation into lipid rafts","volume":"299","author":"Ganapathi","year":"2010","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.tips.2024.06.003_bb0170","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/s41467-021-21681-8","article-title":"Lipid regulation of hERG1 channel function","volume":"12","author":"Miranda","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2024.06.003_bb0175","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/FJC.0b013e318036dd05","article-title":"Hydroxypropyl \u03b2-cyclodextrins: a misleading vehicle for the in vitro hERG current assay","volume":"49","author":"Mikhail","year":"2007","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.tips.2024.06.003_bb0180","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.vascn.2007.04.004","article-title":"Suitability of commonly used excipients for electrophysiological in-vitro safety pharmacology assessment of effects on hERG potassium current and on rabbit Purkinje fiber action potential","volume":"56","author":"Himmel","year":"2007","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.tips.2024.06.003_bb0185","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1080\/17435390.2019.1650969","article-title":"Superparamagnetic iron oxide nanoparticles (SPIONs) modulate hERG ion channel activity","volume":"13","author":"Gualdani","year":"2019","journal-title":"Nanotoxicology"},{"key":"10.1016\/j.tips.2024.06.003_bb0190","doi-asserted-by":"crossref","DOI":"10.1080\/19336950.2023.2287832","article-title":"A structural atlas of druggable sites on Nav channels","volume":"18","author":"Li","year":"2024","journal-title":"Channels (Austin)"}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614724001226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614724001226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T01:25:40Z","timestamp":1723166740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614724001226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0165614724001226"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2024.06.003","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple hERG channel blocking pathways: implications for macromolecules","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2024.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}